SCHEMBL19667307

SCHEMBL19667307

O=C1NCCOc2cc(Br)cc(OCc3ccccc3)c21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.42
PTPN1 P18031 2/20 0.41
MAOB P27338 6/20 0.40
ALDH1A1 P00352 3/20 0.40
MAOA P21397 3/20 0.40
NPC1 O15118 1/20 0.40
HPGD P15428 1/20 0.40
NFKB1 P19838 1/20 0.40
RAB9A P51151 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
SLC6A4 P31645 1/20 0.40
PTP4A3 O75365 1/20 0.40
KDM1A O60341 2/20 0.39
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 1/20 0.37
TTR P02766 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19684894 0.87 GRM5 (0.43) GRM5MAOBALDH1A1MAOANPC1
SCHEMBL19667335 0.80 PARP11 (0.46) PTPN1MAOBMAOASLC6A4PTP4A3
SCHEMBL19684745 0.79 CNR2 (0.35) PTPN1MAOBNFKB1SMN1; SMN2NPSR1
SCHEMBL32691311 0.77 FABP6 (0.38) MAOBALDH1A1HPGDSMN1; SMN2KDM4E
SCHEMBL2983060 0.72 MAOB (0.67) GRM5MAOBALDH1A1MAOANPC1
SCHEMBL2987220 0.71 HTT (0.44) MAOBALDH1A1HPGDSMN1; SMN2MEN1
SCHEMBL19667443 0.71 GRM5 (0.42) GRM5ALDH1A1
SCHEMBL19679348 0.70 FABP6 (0.41) ALDH1A1HPGDKDM4EBLMHTT
SCHEMBL22279020 0.70 HTR2A (0.42) PTPN1MAOB
SCHEMBL19667603 0.70 EGFR (0.44) GRM5PTPN1MAOBMAOASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3464249-B1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER (US) 2021-08-11 EP disclosed
EP-3464249-B1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER (US) 2021-08-11 EP disclosed
US-10709709-B2 Substituted carbonucleoside derivatives useful as anticancer agents PFIZER INC. (US) 2020-07-14 US disclosed
US-20190111060-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2019-04-18 US disclosed
EP-3464249-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Inc (US) 2019-04-10 EP disclosed
US-10220037-B2 Substituted carbonucleoside derivatives useful as anticancer agents PFIZER INC. (US) 2019-03-05 US disclosed
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2017-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10709709-B2 Substituted carbonucleoside derivatives useful as anticancer agents DUT, NCL, TYMP GRM5 4724/4885PTPN1 4606/4885MAOB 3330/4885
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS DUT, NCL, TYMP GRM5 4724/4885PTPN1 4606/4885MAOB 3330/4885
US-20190111060-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS DUT, NCL, TYMP GRM5 4724/4885PTPN1 4606/4885MAOB 3330/4885
US-10220037-B2 Substituted carbonucleoside derivatives useful as anticancer agents DUT, NCL, TYMP GRM5 4724/4885PTPN1 4606/4885MAOB 3330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.